| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
|
N Engl J Med
|
2005
|
33.60
|
|
2
|
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
|
J Clin Oncol
|
2004
|
6.59
|
|
3
|
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2003
|
6.57
|
|
4
|
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.
|
J Clin Oncol
|
2010
|
6.39
|
|
5
|
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
|
J Clin Oncol
|
2008
|
6.31
|
|
6
|
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.
|
Lancet Oncol
|
2007
|
5.39
|
|
7
|
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
|
N Engl J Med
|
2010
|
5.17
|
|
8
|
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2006
|
4.99
|
|
9
|
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
|
J Clin Oncol
|
2011
|
4.81
|
|
10
|
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
|
Lancet Oncol
|
2010
|
4.81
|
|
11
|
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
|
J Clin Oncol
|
2005
|
4.77
|
|
12
|
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
|
J Clin Oncol
|
2012
|
4.57
|
|
13
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
|
N Engl J Med
|
2012
|
4.10
|
|
14
|
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
|
J Clin Oncol
|
2009
|
3.99
|
|
15
|
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
|
J Clin Oncol
|
2002
|
3.82
|
|
16
|
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
|
J Natl Cancer Inst
|
2011
|
3.54
|
|
17
|
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.
|
J Clin Oncol
|
2006
|
2.83
|
|
18
|
Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
|
J Natl Cancer Inst
|
2004
|
2.65
|
|
19
|
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
|
Lancet Oncol
|
2012
|
2.65
|
|
20
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
2.59
|
|
21
|
Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.
|
J Surg Oncol
|
2010
|
2.52
|
|
22
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
|
J Natl Cancer Inst
|
2013
|
2.28
|
|
23
|
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
|
J Clin Oncol
|
2011
|
2.26
|
|
24
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
|
J Clin Oncol
|
2013
|
2.12
|
|
25
|
Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.
|
J Natl Cancer Inst
|
2003
|
2.11
|
|
26
|
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
Breast Cancer Res Treat
|
2011
|
2.08
|
|
27
|
Effect of occult metastases on survival in node-negative breast cancer.
|
N Engl J Med
|
2011
|
1.95
|
|
28
|
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
|
J Clin Oncol
|
2003
|
1.64
|
|
29
|
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
|
J Clin Oncol
|
2011
|
1.56
|
|
30
|
Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials.
|
J Clin Oncol
|
2003
|
1.56
|
|
31
|
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
|
Breast Cancer Res Treat
|
2008
|
1.56
|
|
32
|
Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer.
|
Ann Surg Oncol
|
2008
|
1.48
|
|
33
|
Is sentinel node biopsy necessary in conservatively treated DCIS?
|
Ann Surg Oncol
|
2007
|
1.48
|
|
34
|
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
|
J Clin Oncol
|
2008
|
1.42
|
|
35
|
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
|
Breast Cancer Res Treat
|
2008
|
1.41
|
|
36
|
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
|
J Clin Oncol
|
2002
|
1.32
|
|
37
|
Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
|
J Natl Cancer Inst
|
2013
|
1.21
|
|
38
|
Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
|
Ann Surg Oncol
|
2011
|
1.20
|
|
39
|
Accelerated partial breast irradiation after conservative surgery for breast cancer.
|
Ann Surg
|
2004
|
1.15
|
|
40
|
Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer.
|
J Clin Oncol
|
2008
|
1.14
|
|
41
|
Long-term clinical and radiologic results with autologous fat transplantation for breast augmentation: case reports and review of the literature.
|
Breast J
|
2006
|
1.12
|
|
42
|
A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer.
|
Clin Breast Cancer
|
2010
|
1.00
|
|
43
|
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
|
J Clin Oncol
|
2010
|
0.96
|
|
44
|
Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
|
J Clin Oncol
|
2006
|
0.89
|
|
45
|
Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
|
Clin Breast Cancer
|
2002
|
0.85
|
|
46
|
Review of breast cancer clinical trials conducted by the National Surgical Adjuvant Breast Project.
|
Surg Clin North Am
|
2007
|
0.83
|
|
47
|
Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature.
|
Case Rep Surg
|
2012
|
0.83
|
|
48
|
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.
|
Breast Cancer Res Treat
|
2013
|
0.83
|
|
49
|
Accuracy of a preoperative model for predicting invasive breast cancer in women with ductal carcinoma-in-situ on vacuum-assisted core needle biopsy.
|
Ann Surg Oncol
|
2010
|
0.82
|
|
50
|
Age and lymph node status in breast cancer: not a straightforward relationship.
|
J Clin Oncol
|
2009
|
0.79
|
|
51
|
Evaluation of appropriate short-term mammographic surveillance in patients who undergo breast-conserving Surgery (BCS).
|
Ann Surg Oncol
|
2012
|
0.78
|
|
52
|
Drug development: neoadjuvant opportunities in breast cancer.
|
Am Soc Clin Oncol Educ Book
|
2013
|
0.76
|
|
53
|
Continuing evolution in breast cancer surgical management.
|
J Clin Oncol
|
2005
|
0.75
|
|
54
|
The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.
|
Semin Oncol
|
2008
|
0.75
|
|
55
|
Tailoring loco-regional therapy with neoadjuvant chemotherapy: another step in the right direction.
|
Ann Surg Oncol
|
2004
|
0.75
|
|
56
|
Neoadjuvant Therapy for Early-Stage Breast Cancer: A Model for Individualizing Outcomes and Tailoring Locoregional and Systemic Therapy.
|
Oncology (Williston Park)
|
2015
|
0.75
|
|
57
|
Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy.
|
Breast Cancer Res Treat
|
2009
|
0.75
|
|
58
|
Early-stage breast cancer: new developments and controversies. Preface.
|
Surg Oncol Clin N Am
|
2010
|
0.75
|
|
59
|
The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project.
|
World J Surg
|
2006
|
0.75
|
|
60
|
A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
|
Breast J
|
2003
|
0.75
|